S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
Effects of hyperinsulinemia on sympathetic responses to mental stress
TL;DR: The results suggest that acute hyperinsulinemia during isoglycemic glucose clamp does not interfere with cardiovascular or sympathetic responses to mental stress.
Journal ArticleDOI
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial
Sverre E. Kjeldsen,Gordon T. McInnes,Giuseppe Mancia,Tsushung A. Hua,Stevo Julius,Michael A. Weber,Antonio Coca,Xavier Girerd,Kenneth Jamerson,Pierre Larochelle,Thomas M. MacDonald,Roland E. Schmieder,M. Anthony Schork,Reuven Viskoper,Jiri Widimsky,Alberto Zanchetti +15 more
TL;DR: It is concluded that valsartan compared with amlodipine reduces the risk of developing diabetes mellitus, particularly in hypertensive patients with the highest susceptibility for development of diabetes.
Journal ArticleDOI
Catheter-based renal denervation: a word of caution.
Felix Mahfoud,Sverre E. Kjeldsen +1 more
TL;DR: A first-in-man report of a 75-year-old woman with resistant hypertension who underwent renal denervation using a low-pressure balloon with a mono-polar silver electrode (helical configuration) system and a straightforward radiofrequency ablation is presented.
Journal ArticleDOI
Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy.
Marina K. Christensen,Michael H. Olsen,Kristian Wachtell,Christian Tuxen,Eigil Fossum,Lia E. Bang,Niels Wiinberg,Richard B. Devereux,Sverre E. Kjeldsen,Per Hildebrandt,Jens Rokkedal,Hans Ibsen +11 more
TL;DR: Initial reduction in circulating PICP may predict later regression of LV hypertrophy during losartan‐based antihypertensive treatment, however, initial reduction in circulateable collagen markers after first year of treatment was related to subsequent changes in LV mass index after 2 and 3 years of treatment.